Sarepta's second-gen Duchenne drug shows signs of topping its first

Sarepta Therapeutics has disclosed positive data from a small trial of a drug meant to be a more potent successor to its marketed Duchenne muscular dystrophy treatment Exondys 51, announcing Monday the experimental drug resulted in stronger production of a key muscle-building protein that Duchenne patients lack.